A Phase 2, Multi-Center, Open Label Study Evaluating the Efficacy and Safety of Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Clinical benefit. Clinical benefit is defined as a reduction of secretory symptoms or reduction of quantifiable hormones or other biochemical tumor markers where concomitantly there is an absence of radiological evidence for tumor progression.
monthly for clinical benefit, every two months for tumor progression
No
United States: Food and Drug Administration
C3-07-003
NCT00780663
October 2008
March 2010
Name | Location |
---|---|
Virginia Mason Medical Center | Seattle, Washington 98111 |
Front Range Cancer Specialists | Fort Collins, Colorado 80528 |
Rocky Mountain Cancer Centers | Thornton, Colorado 80260 |
Tyler Cancer Center | Tyler, Texas 75702 |
Northwest Cancer Specialists | Vancouver, Washington 98664 |
Miami, Florida 33176 | |
Texas Oncology | Dallas, Texas |
Birmingham Hematology and Oncology | Birmingham, Alabama 35235 |
El Paso Cancer Treatment Center | El Paso, Texas 79915 |
Cancer Care Centers of South Texas | San Antonio, Texas 78229 |
UT Health Science Center | San Antonio, Texas 78245-3217 |
Southern New Mexico Cancer Center | Las Cruces, New Mexico 88011 |